Research & Literature

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment.

Hitz F, Connors JM, Gascoyne RD, et al.

Annals of hematology 2015; (94(11)):1839-43 doi:10.1007/s00277-015-2467-z.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Xu-Monette ZY, Dabaja BS, Wang X, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(12)):1555-73 doi:10.1038/modpathol.2015.118.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Ye Q, Xu-Monette ZY, Tzankov A, et al.

Oncotarget 2016; (7(3)):2401-16 doi:10.18632/oncotarget.6262.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, et al.

British journal of haematology 2016; (172(2)):246-54 doi:10.1111/bjh.13831.

Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.

Basit A, Siddiqui N, Muzaffar N, et al.

JPMA. The Journal of the Pakistan Medical Association 2016; (66(4)):380-6.

Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective.

Pieterse AH, Kunneman M, Engelhardt EG, et al.

Psycho-oncology 2017; (26(7)):943-950 doi:10.1002/pon.4241.

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

Rosenthal A, Younes A

Blood reviews 2017; (31(2)):37-42 doi:10.1016/j.blre.2016.09.004.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

Seo S, Hong JY, Yoon S, et al.

Oncotarget 2016; (7(47)):76934-76943 doi:10.18632/oncotarget.12734.

Lymphoblastic lymphoma with a triple-hit profile: a rare but distinct and relevant entity.

Hiemcke-Jiwa LS, Leguit RJ, van der Veken LT, et al.

Human pathology 2017; (63()):171-176 doi:10.1016/j.humpath.2016.11.002.

Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Coiffier B, Sarkozy C

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):366-378 doi:10.1182/asheducation-2016.1.366.

Patient and physician views of shared decision making in cancer.

Tamirisa NP, Goodwin JS, Kandalam A, et al.

Health expectations : an international journal of public participation in health care and health policy 2017; (20(6)):1248-1253 doi:10.1111/hex.12564.

[Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature].

Gabeeva NG, Koroleva DA, Belyaeva AV, et al.

Terapevticheskii arkhiv 2017; (89(7)):85-92 doi:10.17116/terarkh201789785-92.

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.

Lu L, Zhu F, Zhang M, et al.

Proceedings of the National Academy of Sciences of the United States of America 2018; (115(3)):E498-E505 doi:10.1073/pnas.1715118115.

Double-hit DLBCL: should we limit FISH testing?

Copie-Bergman C

Blood 2018; (131(18)):1997-1998 doi:10.1182/blood-2018-03-836361.

Cytokine release syndrome: grading, modeling, and new therapy.

Liu D, Zhao J

Journal of hematology & oncology 2018; (11(1)):121 doi:10.1186/s13045-018-0653-x.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, et al.

Clinical lymphoma, myeloma & leukemia 2018; (18(12)):781-787 doi:10.1016/j.clml.2018.08.014.

Shared decision making in oncology: A model based on patients', health care professionals', and researchers' views.

Bomhof-Roordink H, Fischer MJ, van Duijn-Bakker N, et al.

Psycho-oncology 2019; (28(1)):139-146 doi:10.1002/pon.4923.

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Freeman CL, Sehn L

Current oncology reports 2018; (20(12)):103 doi:10.1007/s11912-018-0748-0.

Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

Liu Y, Barta SK

American journal of hematology 2019; (94(5)):604-616 doi:10.1002/ajh.25460.

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.

Gust J, Finney OC, Li D, et al.

Annals of neurology 2019; (86(1)):42-54 doi:10.1002/ana.25502.

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

Tilly H, Morschhauser F, Bartlett NL, et al.

The Lancet. Oncology 2019; (20(7)):998-1010 doi:10.1016/S1470-2045(19)30091-9.

Genetic alterations and their clinical implications in DLBCL.

Miao Y, Medeiros LJ, Li Y, et al.

Nature reviews. Clinical oncology 2019; (16(10)):634-652 doi:10.1038/s41571-019-0225-1.

Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.

Alsharif R, Dunleavy K

Hematology/oncology clinics of North America 2019; (33(4)):587-596 doi:10.1016/j.hoc.2019.04.001.

An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.

Schieppati F, Balzarini P, Fisogni S, et al.

Haematologica 2020; (105(5)):1369-1378 doi:10.3324/haematol.2019.223891.

Revised staging system for malignant lymphoma based on the Lugano classification.

Munakata W, Terauchi T, Maruyama D, Nagai H

Japanese journal of clinical oncology 2019; (49(10)):895-900 doi:10.1093/jjco/hyz111.

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.

Hilton LK, Tang J, Ben-Neriah S, et al.

Blood 2019; (134(18)):1528-1532 doi:10.1182/blood.2019002600.

Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.

Cunningham AM, Harrington AM

Archives of pathology & laboratory medicine 2019; (143(12)):1464-1471 doi:10.5858/arpa.2019-0331-RA.

Spontaneous resolution of untreated diffuse large B-cell lymphoma of maxillary bone after incisional biopsy.

Flatow-Trujillo L, Win K, Jencks A, et al.

Clinical case reports 2019; (7(11)):2082-2086 doi:10.1002/ccr3.2408.

A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

Makita S, Maruyama D, Maeshima AM, et al.

Asia-Pacific journal of clinical oncology 2020; (16(3)):108-114 doi:10.1111/ajco.13248.

Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A.

Sun S, Wang H, Ji M

Technology in cancer research & treatment 2019; (18()):1533033819892256 doi:10.1177/1533033819892256.

A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology.

King JF, Lam JT

Archives of pathology & laboratory medicine 2020; (144(2)):160-167 doi:10.5858/arpa.2019-0182-RA.

Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.

Gupta S, Long SR, Natkunam Y, et al.

Cancer cytopathology 2020; (128(8)):570-579 doi:10.1002/cncy.22286.

Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.

Gleeson M, Counsell N, Cunningham D, et al.

British journal of haematology 2021; (192(6)):1015-1019 doi:10.1111/bjh.16691.

Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.

Berger MD, Trelle S, Büchi AE, et al.

Haematologica 2021; (106(7)):1923-1931 doi:10.3324/haematol.2020.249680.

Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.

Thomsen EA, Rovsing AB, Anderson MV, et al.

Molecular oncology 2020; (14(9)):1978-1997 doi:10.1002/1878-0261.12753.

Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease.

Singh AP, Murray GP, Pandey S

Case reports in pathology 2020; (2020()):4674103 doi:10.1155/2020/4674103.

An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.

Walji M, Assouline S

Expert review of hematology 2020; (13(9)):933-942 doi:10.1080/17474086.2020.1795828.

Dramatic radiotherapy response in a necrotic lymphoma mass: a case report.

McNeil N, Gorayski P, Blunt D, Roos D

Journal of medical case reports 2020; (14(1)):118 doi:10.1186/s13256-020-02438-1.

Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the Middle East and North Africa Region.

Alamer F, Alamir A, Alqahtani A, et al.

Cureus 2020; (12(8)):e9620 doi:10.7759/cureus.9620.

Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.

Chien HC, Morreall D, Patil V, et al.

Future oncology (London, England) 2021; (17(4)):411-422 doi:10.2217/fon-2020-0522.

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.

Collinge B, Ben-Neriah S, Chong L, et al.

Blood 2021; (137(16)):2196-2208 doi:10.1182/blood.2020007193.

Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.

Grana A, Gut N, Williams K, et al.

Clinical lymphoma, myeloma & leukemia 2021; (21(4)):238-245 doi:10.1016/j.clml.2020.10.005.

Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report.

Teixeira da Silva F, Morais Passos R, Esteves A, et al.

Cureus 2020; (12(10)):e11038 doi:10.7759/cureus.11038.

Genetic and epigenetic determinants of diffuse large B-cell lymphoma.

Bakhshi TJ, Georgel PT

Blood cancer journal 2020; (10(12)):123 doi:10.1038/s41408-020-00389-w.

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.

Mitobe M, Kawamoto K, Suzuki T, et al.

Journal of clinical and experimental hematopathology : JCEH 2021; (61(1)):42-47 doi:10.3960/jslrt.20043.

Defining double-hit lymphoma in the clinic.

Blombery P, Lade S

Blood 2021; (137(16)):2132-2133 doi:10.1182/blood.2020009465.

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Morris EC, Neelapu SS, Giavridis T, Sadelain M

Nature reviews. Immunology 2022; (22(2)):85-96 doi:10.1038/s41577-021-00547-6.

Scanxiety: a scoping review about scan-associated anxiety.

Bui KT, Liang R, Kiely BE, et al.

BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

Diffuse Large B-Cell Lymphoma With a Background of Extensive Granulomatous Inflammation: A Potential Pitfall for Misdiagnosis.

Hassanzadeh S, Mackrides N, Rastegar S, Nejati R

Cureus 2021; (13(7)):e16198 doi:10.7759/cureus.16198.

Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma.

Brooks ED, Fang P, Pinnix CC

The British journal of radiology 2021; (94(1127)):20210360 doi:10.1259/bjr.20210360.

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features.

Dholaria B, Vanegas YAM, Diehl N, et al.

Clinical hematology international 2020; (2(3)):117-124 doi:10.2991/chi.d.200410.001.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Tilly H, Morschhauser F, Sehn LH, et al.

The New England journal of medicine 2022; (386(4)):351-363 doi:10.1056/NEJMoa2115304.

Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India.

Moharana L, Dasappa L, Babu S, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2022; (38(1)):15-23 doi:10.1007/s12288-021-01427-8.

MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.

Chen R, Zhou , Wang L, et al.

Therapeutic advances in hematology 2022; (13()):20406207211072839 doi:10.1177/20406207211072839.

Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.

Zanelli M, Sanguedolce F, Zizzo M, et al.

Current oncology (Toronto, Ont.) 2022; (29(2)):956-968 doi:10.3390/curroncol29020081.

Evolution of therapy for limited stage diffuse large B-cell lymphoma.

Rojek AE, Smith SM

Blood cancer journal 2022; (12(2)):33 doi:10.1038/s41408-021-00596-z.

Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.

Ekels A, van de Poll-Franse LV, Posthuma EFM, et al.

British journal of haematology 2022; (197(5)):590-601 doi:10.1111/bjh.18139.

Utility of 18F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma.

Jitani AK, Dutta S, Mandal PK, et al.

The Indian journal of medical research 2021; (154(5)):691-698 doi:10.4103/ijmr.IJMR_1420_19.

Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.

Kuhlman JJ, Moustafa MA, Jiang L, et al.

Clinical lymphoma, myeloma & leukemia 2022; (22(8)):e815-e825 doi:10.1016/j.clml.2022.04.009.

Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.

Hays P

Cancer treatment and research 2022; (183()):287-315 doi:10.1007/978-3-030-96376-7_11.

Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?

Ngu H, Takiar R, Phillips T, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-14 doi:10.1200/EDBK_349307.

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Kamdar M, Solomon SR, Arnason J, et al.

Lancet (London, England) 2022; (399(10343)):2294-2308 doi:10.1016/S0140-6736(22)00662-6.

The multiple roles of LDH in cancer.

Claps G, Faouzi S, Quidville V, et al.

Nature reviews. Clinical oncology 2022; (19(12)):749-762 doi:10.1038/s41571-022-00686-2.

External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.

Warnnissorn N, Kanitsap N, Niparuck P, et al.

Hematology (Amsterdam, Netherlands) 2022; (27(1)):1237-1245 doi:10.1080/16078454.2022.2147916.

Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance.

Panda D, Das N, Thakral D, Gupta R

Journal of the Egyptian National Cancer Institute 2022; (34(1)):52 doi:10.1186/s43046-022-00154-z.

Transformation of diffuse large B-cell lymphoma to lymphoblastic lymphoma.

Kushwaha P, Singh M, Mallya V, et al.

Journal of cancer research and therapeutics 2022; (18(Supplement)):S475-S477 doi:10.4103/jcrt.jcrt_66_21.

PET/CT in Non-Hodgkin Lymphoma: An Update.

Zanoni L, Bezzi D, Nanni C, et al.

Seminars in nuclear medicine 2023; (53(3)):320-351 doi:10.1053/j.semnuclmed.2022.11.001.

Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma.

Lee KR, Lee JO, Lee JS, Paik JH

Journal of Cancer 2022; (13(15)):3598-3605 doi:10.7150/jca.67569.

The Immunology of DLBCL.

Takahara T, Nakamura S, Tsuzuki T, Satou A

Cancers 2023; (15(3)) doi:10.3390/cancers15030835.

Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.

Sheng Z, Li D, Chen B, et al.

Annals of hematology 2023; (102(5)):1011-1017 doi:10.1007/s00277-023-05161-1.

Inflammatory Presentation of a Primary Extranodal Diffuse Large B-cell Lymphoma of the Maxillary Sinus.

Cerqueira É, Colino M, Almeida R, et al.

Cureus 2023; (15(4)):e38008 doi:10.7759/cureus.38008.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Westin JR, Oluwole OO, Kersten MJ, et al.

The New England journal of medicine 2023; (389(2)):148-157 doi:10.1056/NEJMoa2301665.

Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.

Gao J, Dahiya S, Patel SA

British journal of haematology 2023; (203(2)):161-168 doi:10.1111/bjh.19001.

Update on bi-specific monoclonal antibodies for blood cancers.

Shouse G

Current opinion in oncology 2023; (35(5)):441-445 doi:10.1097/CCO.0000000000000966.

Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.

Matarasso S, Assouline S

Future oncology (London, England) 2023; (19(31)):2083-2101 doi:10.2217/fon-2023-0274.

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.

Kelkar AH, Cliff ERS, Jacobson CA, et al.

Annals of internal medicine 2023; (176(12)):1625-1637 doi:10.7326/M22-2276.

The effect of mindfulness-based interventions on biomarkers in cancer patients and survivors: A systematic review.

Matiz A, Scaggiante B, Conversano C, et al.

Stress and health : journal of the International Society for the Investigation of Stress 2024; (40(4)):e3375 doi:10.1002/smi.3375.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Integration of PET in DLBCL.

Lewis KL, Trotman J

Seminars in hematology 2023; (60(5)):291-304 doi:10.1053/j.seminhematol.2023.12.003.

The value of bispecific antibodies in relapsed and refractory DLBCL.

Lewis KL, Cheah CY

Leukemia & lymphoma 2024; (65(6)):720-735 doi:10.1080/10428194.2024.2323085.

A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.

Jelicic J, Juul-Jensen K, Bukumiric Z, et al.

European journal of haematology 2025; (114(1)):26-36 doi:10.1111/ejh.14301.

Prostate tuberculosis mimicking malignancy on 18F-FDG PET/CT in a patient with diffuse large B-cell lymphoma: A case report.

Bai M, Yu Q, Yuan L, et al.

Medicine 2024; (103(22)):e38296 doi:10.1097/MD.0000000000038296.

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.

Sarraf Yazdy M, Kasamon YL, Gu W, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(24)):5521-5526 doi:10.1158/1078-0432.CCR-24-1729.

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations.

Varon B, Horowitz NA, Khatib H

Patient preference and adherence 2024; (18()):2159-2167 doi:10.2147/PPA.S485838.

Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.

Zhao P, Zhao S, Huang C, et al.

Hematological oncology 2025; (43(1)):e70017 doi:10.1002/hon.70017.

Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.

Guo Y, Lian J, Chen Y, et al.

Hematology (Amsterdam, Netherlands) 2025; (30(1)):2445395 doi:10.1080/16078454.2024.2445395.

Primary large B-cell lymphoma of the patella with early systemic progression: A case report.

Ben Rejeb S, Ben Romdhane M, Sghaier M, Charfi M

International journal of surgery case reports 2025; (131()):111344 doi:10.1016/j.ijscr.2025.111344.

Clinico-pathologic Profile of Filipino Patients Diagnosed with Diffuse Large B-Cell Lymphoma, Germinal Center or Non-germinal Center Subtype Treated in a Public Tertiary Hospital from 2016 to 2021.

Cancio JEG, Damian KB, Villanueva EQ, et al.

Acta medica Philippina 2025; (59(5)):58-64 doi:10.47895/amp.vi0.9688.

Primary Diffuse Large B-Cell Lymphoma of the Seminal Vesicles: A Rare Case With Diagnostic and Therapeutic Implications.

Soleimani M, Farajpour M, Kazeminejad B

Clinical case reports 2025; (13(6)):e70489 doi:10.1002/ccr3.70489.

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.

Shen J, Zhang J, Zhu Z, et al.

Frontiers in oncology 2025; (15()):1641769 doi:10.3389/fonc.2025.1641769.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Morschhauser F, Salles G, Sehn LH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(35)):3698-3705 doi:10.1200/JCO-25-00925.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

A case of primary cutaneous diffuse large B-cell lymphoma, leg type with MYC rearrangement and high BCL2 protein expression due to trisomy 18.

Matsui Y, Katsumi A, Tanaka K, et al.

Nagoya journal of medical science 2025; (87(3)):582-589 doi:10.18999/nagjms.87.3.582.

Exploring Key Elements of Surgical Shared Decision Making for Providers and Older Adults.

Poles G, Erlick M, Zimmer A, Russell M

MDM policy & practice 2025; (10(2)):23814683251382259 doi:10.1177/23814683251382259.

Fatigue, Neuropathy and Psychological Distress and Their Association With Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison With a Normative Population.

Neppelenbroek SIM, Ekels A, Kersten MJ, et al.

Hematological oncology 2025; (43(6)):e70151 doi:10.1002/hon.70151.

A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma.

Wang Y, Wang X, Huang XY, et al.

Cell reports. Medicine 2025; (6(11)):102452 doi:10.1016/j.xcrm.2025.102452.

Benign thyroid nodule mimicking residual disease on positron emission tomography/computed tomography in a patient with concurrent thyroid and gastric diffuse large B-cell lymphoma: the value of ultrasound-guided biopsy.

Tatoğlu MT, Özsoy MS

Journal of ultrasound 2026; doi:10.1007/s40477-026-01122-2.